THE DEVELOPMENT & PILOT IMPLEMENTATION OF A CAS13A-BASED LOW-COST POINT-OF-CARE ASSAY FOR DETECTING NEISSER…
Federal financial assistance recorded from USAspending. This is not a procurement contract.
Research this with AI
Research smarter with AI
Analyze opportunities and compare insights across leading AI models.
ASST_NON_K23AI182453_075 · BRIGHAM & WOMENS HOSPITAL INC · Department of Health and Human Services
Compare Multiple AI Models with SmartSoloExplore CaptureIQ IntelligenceAssistance award details
- Assistance award identifier
- ASST_NON_K23AI182453_075
- FAIN
- K23AI182453
- Recipient
- BRIGHAM & WOMENS HOSPITAL INC
- Awarding agency
- Department of Health and Human Services
- Funding agency
- Department of Health and Human Services
- Assistance listing (CFDA)
- 93.855
- Total obligated
- $585,098
- Period
- Aug 19, 2024 – Jul 31, 2029
- Fiscal year
- 2024
- Place of performance state
- MA
- Source file
- FY2024_All_Assistance_Full_20261006.zip
Description
THE DEVELOPMENT & PILOT IMPLEMENTATION OF A CAS13A-BASED LOW-COST POINT-OF-CARE ASSAY FOR DETECTING NEISSERIA GONORRHOEAE AND MOLECULAR MARKERS OF ANTIMICROBIAL RESISTANCE IN RESOURCE-LIMITED SETTINGS - PROJECT SUMMARY LOW-RESOURCE SETTINGS HAVE A HIGH BURDEN OF NEISSERIA GONORRHOEAE INFECTION, BUT INSUFFICIENT LABORATORY INFRASTRUCTURE FOR DIAGNOSTIC TESTS AND ANTIMICROBIAL SUSCEPTIBILITY DETERMINATION, LEADING TO SYNDROMIC MANAGEMENT, WHICH MISSES A HIGH PROPORTION OF CASES AND RESULTS IN THE OVERUSE OF ANTIBIOTICS. TOGETHER, THOSE FACTORS CONTRIBUTE TO DRIVING THE EMERGENCE OF ANTIMICROBIAL RESISTANCE (AMR), A GLOBAL PUBLIC HEALTH THREAT. TWO NOVEL STRATEGIES CAN COMBINE TO ADDRESS THOSE CHALLENGES. FIRST, THE USE OF CRISPR-BASED TECHNOLOGY PERMITS THE DEVELOPMENT OF LOW-COST, POINT-OF-CARE (POC) ASSAYS, WHICH CAN BE USED IN RESOURCE-LIMITED SETTINGS. SECOND, DETERMINATION OF MOLECULAR RESISTANCE MARKERS CAN FACILITATE RESISTANCE-GUIDED THERAPY, THEREBY REDUCING THE SELECTIVE PRESSURE TOWARDS AMR. THE STUDY AIMS ARE: 1) ADAPT AND VALIDATE EXISTING CRISPR-BASED ASSAYS FOR POC DETECTION OF N. GONORRHOEAE AND CIPROFLOXACIN SUSCEPTIBILITY, 2) DEVELOP A MULTIPLEXED CRISPR-BASED ASSAY FOR N. GONORRHOEAE CEFIXIME SUSCEPTIBILITY, AND 3) EVALUATE THE FEASIBILITY AND ACCEPTABILITY OF THE POC N. GONORRHOEAE AND AMR ASSAYS AMONG TWO HEALTH CENTERS IN BOTSWANA. THE STUDY IS BASED UPON OUR PRELIMINARY WORK IN THE DEVELOPMENT OF CAS13A-BASED DIAGNOSTICS FOR N. GONORRHOEAE AND CIPROFLOXACIN SUSCEPTIBILITY, AND WILL LEVERAGE CLINICAL SPECIMENS COLLECTED AS A PART OF AN ONGOING TRIAL AT THE MASSACHUSETTS GENERAL HOSPITAL SEXUAL HEALTH CLINIC, AS WELL AS THROUGH EXISTING COLLABORATIONS IN BOTSWANA. THIS MENTORED PATIENT-ORIENTED RESEARCH CAREER DEVELOPMENT AWARD (K23) SUPPORTS THE CAREER DEVELOPMENT OF DR. LAO-TZU ALLAN-BLITZ, AN INSTRUCTOR OF MEDICINE WITH EXPERIENCE IN THE EPIDEMIOLOGY OF AND NOVEL DIAGNOSTIC ASSAYS TARGETING AMR SEXUALLY TRANSMITTED INFECTIONS (STI). THE K23 WIL